A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases

February 7, 2018 updated by: Zhang Helong, Tang-Du Hospital

A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases

An observational study to explore prognoses and clinical treatments of the patients with non-small cell lung cancer complicated with oligometastases

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

A multi-centre real-world non-interventional observational study to explore prognoses and clinical treatments of the patients with non-small lung cancer complicated with oligometastases

Study Type

Observational

Enrollment (Anticipated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100029
        • Recruiting
        • China-Japan Friendship Hospital
        • Contact:
        • Principal Investigator:
          • Deruo Liu, PhD
      • Beijing, Beijing, China, 100853
        • Recruiting
        • China PLA General Hospital
        • Contact:
        • Principal Investigator:
          • Yang Liu, PhD
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Recruiting
        • Henan Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Yin Li, PhD
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Recruiting
        • Tongji Hospital Affiliated to Huazhong Technology Hospital
        • Contact:
        • Principal Investigator:
          • Xiangning Fu, PhD
    • Jiangsu
      • Nanjing, Jiangsu, China, 210009
        • Recruiting
        • Jiangsu Cancer Hospital
        • Contact:
        • Principal Investigator:
          • Lin Xu, PhD
    • Shaanxi
      • Xi'an, Shaanxi, China, 710000
        • Recruiting
        • Xi'an Tangdu Hospital
        • Contact:
        • Principal Investigator:
          • Xiaofei Li, PhD
    • Shanghai
      • Shanghai, Shanghai, China, 200030
        • Recruiting
        • Shanghai Chest Hospital
        • Principal Investigator:
          • Heng Zhao, PhD
        • Contact:
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recruiting
        • Huaxi Hospital Affiliated to Sichuan University
        • Contact:
        • Principal Investigator:
          • Lunxu Liu, PhD
    • Tianjin
      • Tianjin, Tianjin, China, 300051
        • Recruiting
        • Tianjin Chest Hospital
        • Contact:
        • Principal Investigator:
          • Xun Zhang, PhD
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • Recruiting
        • First Hospital Affiliated to Zhejiang University
        • Contact:
        • Principal Investigator:
          • Jian Hu, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Pathologically diagnosed patients with non-small cell lung cancer

Description

Inclusion Criteria:

  • Pathologically diagnosed patients with non-small cell lung cancer;
  • Tumor metastases in one organ (no more than 3 metastases);

Exclusion Criteria:

  • Patients with intrapulmonary metastases or multiple primary tumors;
  • Patients with pleural dissemination or invasion of extrapulmonary organs;
  • Patients with supraclavicular lymph node metastasis;
  • Patients with systematic diseases that would influence patient survivals;
  • Patients with no records for visits;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with surgeries
NSCLC patients with surgeries
Procedure: Surgeries
Surgeries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: 2014 - 2017
Overall survival
2014 - 2017

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disease-free survival
Time Frame: 2014 - 2017
Disease-free survival
2014 - 2017

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tang-Du Hospital

Collaborators

LinkDoc Technology (Beijing) Co. Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 31, 2017

Primary Completion (Anticipated)

April 30, 2018

Study Completion (Anticipated)

April 30, 2018

Study Registration Dates

First Submitted

February 2, 2018

First Submitted That Met QC Criteria

February 7, 2018

First Posted (Actual)

February 9, 2018

Study Record Updates

Last Update Posted (Actual)

February 9, 2018

Last Update Submitted That Met QC Criteria

February 7, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WTONG05

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe